Zentalis shakes up PhIII plans in ovarian cancer; Halozyme's deal with Acumen; Korro's $117M private placement

06 Nov 2023

Phase 2Phase 1Phase 3

Zentalis Pharma shakes up plans for Phase III in ovarian cancer: Zentalis announced Monday that it is no longer planning to test its lead candidate, azenosertib, in combination with chemotherapy in second-line platinum-sensitive ovarian cancer (PSOC) patients. The Phase III study was expected to start in the first quarter of next year. Instead, the company plans to test the wee1 inhibitor wee1 inhibitor as a first-line maintenance treatment for PSOC, pushing back the timeline for beginning a Phase III trial into 2025. Zentalis also shared updated results from a Phase I study in platinum-resistant ovarian cancer. The biotech is currently running a Phase II trial for which it plans to share topline data in 2025. Zentalis {ZNTL} shares fell over 20% after markets opened Monday. — Lei Lei Wu

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Acumen CNA Training

Korro Bio, Inc. (United States)

Zentalis Pharmaceuticals, Inc.

Indications

Ovarian CancerPlatinum-Sensitive Ovarian CarcinomaPlatinum-Resistant Ovarian Carcinoma

Targets

WEE1

Drugs

AzenosertibSTC-8123

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.